Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338
Tenon Medical raises about $2.9 million through a warrant inducement deal that also issues a large block of new investor warrants.
Rhea-AI Summary
Tenon Medical (TNON) closed a warrant inducement transaction on September 14, 2026 with an institutional investor, generating gross cash proceeds of approximately $2.87 million.
The investor exercised outstanding warrants to purchase an aggregate of 572,179 common shares. In return, the investor received new unregistered warrants to buy up to 858,269 additional shares, equal to 150% of the shares issued upon the exercise of the existing warrants, with an exercise price of $5.02 per share. The New Warrants are immediately exercisable and expire five years from issuance. Gross proceeds of $2,872,338.58 exclude any future proceeds from New Warrant exercises and are stated before advisor fees and other expenses. WallachBeth Capital acted as financial advisor. The company plans to file a resale registration statement for the New Warrant shares.
Positive
- Gross cash proceeds of approximately $2,872,338.58 from warrant exercises, before fees and expenses
- Potential for additional cash if up to 858,269 New Warrants are exercised at $5.02 per share
- New Warrants are immediately exercisable and have a five-year term, providing flexibility for future capital inflow
Negative
- Immediate issuance of 572,179 new common shares increases share count and investor dilution
- New Warrants for up to 858,269 additional shares create future dilution overhang
- New Warrants and underlying shares are initially unregistered, limiting liquidity until the resale registration becomes effective
News Explained
Gross proceeds equal 94.8 days of second-quarter operating cash outflow, while reported cash equaled 55.3 days at that rate.
The transaction is closed: Tenon Medical received gross cash, its common-share count increased, and up to
The new warrants are not common shares yet; they are immediately exercisable rights issued in a private placement. If exercised, issuing those shares would reduce existing holders’ percentage ownership absent offsetting changes.
The
Sources and calculations
- Tenon Medical warrant inducement closing release (2026-09-14)
- Dilution definition (2026-07-17)
- Tenon Medical latest-quarter fundamentals (2026-06-30)
- Offering gross against the last reported quarterly operating outflow, in days at that rate $2,872,338 / ($2,758,000 / 91) = 94.8 days
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $1,677,000 / ($2,758,000 / 91) = 55.3 days
Details
Market reaction after warrant inducement closing: TNON -4.38%
Following this news, TNON has declined 4.38%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 34 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $5.67. Trading volume is exceptionally heavy at 23.0x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Gross proceeds
- $2,872,338.58
- Warrant inducement closing, before fees and expenses
- Existing warrants exercised
- 572,179 shares
- Immediate exercise in full
- New warrant shares
- 858,269 shares
- Equal to 150% of shares issued upon existing warrant exercise
- New warrant exercise price
- $5.02 per share
- New warrants
- New warrant term
- Five years
- From date of issuance
- Resale registration
- 1 registration statement
- Shares issuable upon exercise of the New Warrants
Historical Context
-
Announcement described immediate exercise of 572,179 warrants for $2,872,338.58 gross proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
warrant inducement financial
private placement financial
resale registration statement regulatory
unregistered warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS GATOS, CA / ACCESS Newswire / September 14, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced today it has closed its previously announced warrant inducement agreement with an institutional investor to exercise outstanding warrants to purchase an aggregate of 572,179 of the Company's shares of common stock (the "Existing Warrants").
In consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds of
The gross proceeds from the warrant inducement were
WallachBeth Capital acted as financial advisor for the warrant inducement transaction.
The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the New Warrants (the "Resale Registration Statement").
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.
For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+™ are also trademarks of Tenon Medical, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
Investor Contact
Shannon Devine
MZ North America
203-741-881
tenon@mzgroup.us
SOURCE: Tenon Medical
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.